Amgen vs TotalEnergies: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. TotalEnergies was founded in 1924 by Raymond Poincaré, Ernest Mercier and is led by Patrick Pouyanné.
Company facts
Amgen
- Founded
- 1980
- Headquarters
- Thousand Oaks, California
- Current CEO
- Robert A. Bradway
- Employees
- 31,500
TotalEnergies
- Founded
- 1924
- Headquarters
- Paris, France
- Current CEO
- Patrick Pouyanné
- Employees
- 100,000
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
TotalEnergies
Raymond Poincaré
Raymond Poincaré was President of France during World War I and Prime Minister when his government pushed for a national oil company in 1924.
Ernest Mercier
Ernest Mercier was the industrialist chosen to set up and chair Compagnie Française des Pétroles.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
TotalEnergies
- Thierry Desmarest1995–2007
Chairman and Chief Executive Officer
Under his leadership, Total more than doubled in size, becoming a dominant global supermajor capable of competing with Exxon and Shell.
Source - Christophe de Margerie2007–2014
Chairman and Chief Executive Officer
He transformed Total into one of the most geographically diverse supermajors before his sudden death in a plane crash in 2014.
Source - Patrick Pouyanné2014–present
Chairman and Chief Executive Officer
CEO since October 2014 and Chairman since December 2015, Pouyanné renamed the company TotalEnergies in 2021, expanded LNG and Integrated Power, and kept returns at the top of the majors (12.6% ROACE in 2025).
Source - Jean-Pierre Sbraire2019–present
Chief Financial Officer
As CFO, he fortified the balance sheet during unprecedented energy market volatility following the geopolitical shocks of 2022.
Source
Timeline: Amgen and TotalEnergies side by side
1924TotalEnergies
Compagnie Francaise des Petroles founded
The French state-backed oil company was created to secure access to petroleum resources and became the predecessor of TotalEnergies.
1954TotalEnergies
Total Brand Created
The company created the Total brand in 1954 to build a retail distribution network.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1995TotalEnergies
Thierry Desmarest becomes CEO
Thierry Desmarest became CEO of TotalEnergies in 1995. Led Total from 1995 to 2007 and engineered the Petrofina and Elf Aquitaine combinations; remained Chairman until 2010.
1999TotalEnergies
Petrofina acquired; Elf Aquitaine follows in 2000
Total combined with Belgium's Petrofina in 1999 and Elf Aquitaine in 2000, operating as TotalFinaElf before reverting to Total in 2003.
2000TotalEnergies
Elf Aquitaine Acquired
Total acquired Elf Aquitaine in 2000, forming TotalFinaElf.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2007TotalEnergies
Christophe de Margerie becomes CEO
Christophe de Margerie became CEO of TotalEnergies in 2007. CEO from 2007 and Chairman from 2010 until his death in a plane accident at Moscow's Vnukovo airport in October 2014.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2011TotalEnergies
Acquired SunPower (majority stake)
TotalEnergies acquired SunPower (majority stake).
2018TotalEnergies
Direct Energie acquired
Total bought French power and gas retailer Direct Energie, the base of its European retail electricity business.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2021TotalEnergies
Total becomes TotalEnergies
The company changed its name to TotalEnergies to reflect a broader multi-energy strategy spanning oil, gas, electricity, renewables, and low-carbon energy.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025TotalEnergies
2025 results
Revenues from sales of $182.344 billion, adjusted net income of $15.6 billion (down 15%), IFRS net income of $13.127 billion and a €3.40 dividend.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026TotalEnergies
Mozambique LNG full restart
On January 29, 2026, Patrick Pouyanné and President Daniel Chapo announced the full restart of the roughly $20 billion Mozambique LNG project after force majeure was lifted in November 2025.
2026TotalEnergies
Q2 2026 results
Adjusted net income of $6.0 billion and cash flow of $9.8 billion in the second quarter as higher oil prices tied to the Middle East conflict lifted earnings.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
TotalEnergies
- Direct Energie2018$1.6B
- Saft Groupe2016Undisclosed
- SunPower (majority stake)2011Undisclosed
- Petrofina and Elf Aquitaine1999Undisclosed
Questions about Amgen vs TotalEnergies
Who is the CEO of Amgen Inc. and TotalEnergies SE?
Amgen Inc. is led by Robert A. Bradway and TotalEnergies SE is led by Patrick Pouyanné. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs TotalEnergies SE?
TotalEnergies SE was founded in 1924 — 56 years before Amgen Inc., which was founded in 1980. TotalEnergies SE's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to TotalEnergies SE?
Amgen Inc. employs approximately 31,500 people, while TotalEnergies SE employs approximately 100,000. TotalEnergies SE has the larger workforce at 100,000 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and TotalEnergies SE headquartered?
Amgen Inc. is headquartered in United States and TotalEnergies SE is headquartered in France. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and TotalEnergies SE?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. TotalEnergies SE was founded by Raymond Poincaré, Ernest Mercier.
Which company has a longer operating history — Amgen Inc. or TotalEnergies SE?
TotalEnergies SE has been operating for approximately 102 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs TotalEnergies overview